CytRx Identifies RNAi Drug Candidate for Animal Testing, CEO Downplays Significance of Suits

The development is noteworthy because CytRx has recently shifted the majority of its focus away from its preclinical RNAi programs to its small molecule and DNA vaccine efforts, suggesting that drug research has taken a back seat to other R&D activities at the company. Subscribers: click headline for more

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.